ABSI Absci Corporation Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
00:16
Jun 30
Jun 30
Author sold their ABSI position after hitting a target but notes it may go higher and that another trader added it to their portfolio today.
LOW
10:59
Jun 18
Jun 18
States a short-term trade for Absi and longer holds for Abcl and IOVA, but provides no catalyst or directional reasoning.
LOW
10:44
Jun 18
Jun 18
Buy ABSI as a play on AI-augmented biotech/digital biology convergence; author frames this as a high-regret-risk omission for portfolios lacking exposure to the trend.
MED
15:42
Jun 04
Jun 04
Author identifies ABSI as a proteonomics/AI antibody stock moving in the biotech sector, no directional view.
LOW
14:55
Jun 04
Jun 04
Author evaluates three biotech tickers as potential long-term holds depending on clinical data, explicitly ruling out ABSI, but offers no personal position or forward call.
LOW
14:50
Jun 04
Jun 04
Author reiterates a prior bullish biotech thesis from research discord but provides no current position disclosure or forward directional call in the tweet itself.
10:29
Jun 02
Jun 02
The author corrects a parent claim by noting AMD has capital deals with biotech firms for proteonomics, citing ABSI as one example without taking a directional position.
LOW
00:56
Jun 02
Jun 02
Author explicitly says ABSI, ABCL, and IOVA are their bets on the digital biology narrative, which they expects to run hard.
MED
18:12
May 29
May 29
Author discloses a current long position in ABSI alongside ABCL as a bet on AI-driven personalized medicine and digital biology becoming a major sector within five years.
MED
16:18
May 06
May 06
Holding spot ABSI after taking 268% profit on calls; sees it running to ~$9 on insider open-market buying.
HIGH
17:53
May 04
May 04
Holds ABSI calls up 200% — bullish, 'there's always a bull market somewhere'.
MED
01:51
May 01
May 01
Holds ABSI calls up 185% in 2 weeks; conviction from insider buys by ex-Philips CEO and ex-AstraZeneca EVP.
HIGH
15:32
Apr 27
Apr 27
Holds ABSI calls bought at $3.15, now up 105% — 'there's always a bull market somewhere'.
MED
10:22
Apr 19
Apr 19
Likes Absci; accommodating FDA + AI-augmented biotech R&D thesis, accumulate equity pullbacks.
MED
17:38
Apr 17
Apr 17
Names Absci as a current pick (AI-biotech / FDA thesis restated from prior posts).
LOW
03:20
Apr 17
Apr 17
Bull case for Absci: AI proliferating oncology/therapeutics; highlights ABSI funded through 2028 as de-risking the long.
MED
About ABSI Analyst Coverage
Buzzberg tracks ABSI (Absci Corporation Common Stock) across 1 sources. 10 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (62%). 16 total trade ideas tracked. Latest voices: CryptoCondom, crypto_condom.